Training activity information
Details
Report results of a patient who has received an immunotherapy leading to potential secondary immunodeficiency for at least two of the following:
- Monoclonal antibody therapy
- Immunosuppressive drugs
- Physical methods of immunosuppression
- Cytokines and anti-cytokines
- Cell therapy
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Considerations
- Mechanism of immunotherapeutic interventions
- Consequences of immunotherapeutic interventions
- Monitoring tests
- Follow on testing
- Outcome measures
- Local and national guidelines
- Referral pathway
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What is your understanding of how these specific immunotherapies can lead to secondary immunodeficiency? What key laboratory parameters need to be monitored in patients receiving these therapies to detect potential secondary immunodeficiency ?
- What is your current understanding of these immunotherapeutic agents? What challenges might you face in interpreting and reporting these results in a clinically meaningful way, and how will you address them?
- How will you prepare for reporting these results? Will you review the mechanisms of action of the listed immunotherapies and their potential impact on immune parameters? Will you consider how to present these results with appropriate clinical context and interpretation?
In action
- How are you assessing the likelihood of secondary immunodeficiency based on the observed changes? What are the key points you need to include in your report to clearly communicate the potential impact of the immunotherapy on the patient’s immune system?
- What are the key points you need to include in your report to clearly communicate the potential impact of the immunotherapy on the patient’s immune system?
On action
- Summarise the key immunological results of the patient you reported on and the type(s) of immunotherapy they received. How might these therapies lead to secondary immunodeficiency?
- What did you learn about the potential immunological side effects of different immunotherapies? Were there any challenges in interpreting the results or linking them to the immunotherapy? Why is it crucial to consider a patient’s treatment history when interpreting their immunological results?
- What specific immunotherapies and their potential impact on the immune system would you like to learn more about? What resources or collaborations with clinical teams could enhance your understanding in this area?
Beyond action
- Since reporting on this case, have you encountered other patients receiving immunotherapies with potential secondary immunodeficiency?
- How did this earlier experience influence your subsequent reporting and interpretation of results?
- How has this DTA improved your understanding of the interplay between immunotherapy and the immune system?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 2 |
Outcome
Interpret and report on laboratory investigations that enumerate components of this immune system and its function in light of clinical details and other laboratory tests. |